Icon

Adempas - (0.5, 1, 1.5, 2, 2.5 mg; Tablet, Oral)

Riociguat Bayer
0.5, 1, 1.5, 2, 2.5 mg; Tablet, Oral
Less Than $1000 mn
Less Than 5
Less Than 5
More Than 5
None
Less Than 5
None
Indicated for Treatment of persistent/recurrent chronic thromboembolic pulmonary hypertension (CTEPH), (WHO Group 4) after surgical treatment, or inoperable CTEPH, to improve exercise capacity and WHO functional class.
Yes
**** *** *** **** *** *** ***** ** **** **** ** **** ******* '*** (*** *, ****). ****** *** ****** ** ** ****** **** ********** *** ********* **** **** ***** *** ***** ** ********* *** *** *****. **** ****** ****** ****** *** *, **** *.*. ****** **** *********** ****** ** *** *******. *** **** ** **** *********. ****** '*** *** ***** ********* ** ** **** **, ****. ***** ** *** **** ******* *** *** *******. ********* ** *****'* *** ******, *** ******** ****** ** ******* ** *** ****** ** ******. **, **** ** *** ******** *** ****** *** ******* ****** ******.
Adempas Patent 1 Patent 2 Patent 3 Patent 4
**** ******* ******* *** ********* *** ********* (***** ******)
*** **** *** ********* ******* ******* *** ********* (***** ******)
******* ********* ******* ******* *******
Company FTF Status / 180 days exclusivity 30-Months stay Current Litigation Status Current Approval Status Likelihood of launch
**** *** \ ********* **** **, **** ******* **** *** ****** *** ****
*** **** *** \ ********* **** **, **** ******* ******** ******* ****** *** ****
******* *** \ ********* **** **, **** ******* **** ******* *** **** *** *** ****
  1. *** **, **** : **** & *** **** ********** ******** ***** ***** *** **** ** **** ****** '*** (*** *, ****).
  2. *** **, **** : ***** ***** * **** ******* **** & *** **** ** ******** ***** ** ********.
  3. *** **, **** : ********** ********* **** **** *** ****** '*** (*** *, ****) *.*. **** ****** ** ****, **** **** ********* *** ****** ** ** ***** *** ********* ** ****'* ****
  4. *** **, **** : *** **** ******** ***** ***** *** **** ** **** ****** '***.
  5. *** **, **** : ***** ***** * **** ******* *** **** ** ****** '***.
  6. *** **, **** : ********** ********* **** ********* **** *** **** *** **** ******.
  7. :
  8. *** **, **** : ***** ***** ******* **** ******* *******, **** ************ ** ******* '*** *** '*** (***** ******) **** ******** ** *** **, ****
  9. *** *, **** : ***** ***** * ***** **** ******* *******, **** ************ ** ****** '*** (*** *, ****)
  10. *** **, **** : ***** *** ******* ******* ********* **********. ** ****** ** ** **********.

Download ParaIV Report


Download ParaIV Detailed Report


To get detailed report Contact Us

ParaIV Advanced Search






Drug Name Generic Name Dosage Route of Administration Probable FTF Known Para IV Filers Other ANDA Developers

Please contact contact@researchdelta.com to get more details.